Cargando…
Reduced O-GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney
Diabetic kidney disease is a worldwide epidemic, and therapies are incomplete. Clinical data suggest that improved renal outcomes by Na(+)-glucose cotransporter 2 inhibitor (SGLT2i) are partly beyond their antihyperglycemic effects; however, the mechanisms are still elusive. Here, we investigated th...
Autores principales: | Hodrea, Judit, Balogh, Dora B., Hosszu, Adam, Lenart, Lilla, Besztercei, Balazs, Koszegi, Sandor, Sparding, Nadja, Genovese, Federica, Wagner, Laszlo J., Szabo, Attila J., Fekete, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Physiological Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242633/ https://www.ncbi.nlm.nih.gov/pubmed/32116017 http://dx.doi.org/10.1152/ajprenal.00021.2020 |
Ejemplares similares
-
RAAS inhibitors directly reduce diabetes‐induced renal fibrosis via growth factor inhibition
por: Koszegi, Sandor, et al.
Publicado: (2018) -
Mass Spectrometry for O-GlcNAcylation
por: Yin, Ruoting, et al.
Publicado: (2021) -
The role of O-GlcNAcylation in development
por: Czajewski, Ignacy, et al.
Publicado: (2023) -
O-GlcNAcylation: The Sweet Side of the Cancer
por: de Queiroz, Rafaela Muniz, et al.
Publicado: (2014) -
O-GlcNAcylation and Metabolic Reprograming in Cancer
por: Jóźwiak, Paweł, et al.
Publicado: (2014)